AJP Reports最新文献

{"title":"Sickle Cell Vaso-Occlusive Crisis Leading to Uteroplacental Malperfusion: A Case Report.","authors":"Annika van Oosbree, Gretchen Hahn, Sarah Shea","doi":"10.1055/a-2849-8204","DOIUrl":"https://doi.org/10.1055/a-2849-8204","url":null,"abstract":"<p><p><b>Background</b> Sickle cell disease (SCD) in pregnancy is associated with substantially increased risks of stillbirth and neonatal death due to vaso-occlusive crises, chronic anemia, and impaired placental perfusion. <b>Case</b> We present the case of a 25-year-old primigravida with HbSS disease who presented at 29 weeks' gestation with a vaso-occlusive pain crisis. Although she was initially clinically stable with reassuring fetal testing, she developed acute fetal distress on hospital day 3, prompting an emergent cesarean delivery. Intraoperatively, the uterus appeared profoundly hypoperfused with minimal bleeding despite uterine atony. The neonate was delivered in asystole and required prolonged resuscitation. Postresuscitation examination raised concern for severe hypoxic ischemic encephalopathy, and the parents elected to transition to comfort care. The neonate died shortly after withdrawal of life-sustaining interventions. Placental pathology demonstrated prominent sickled erythrocytes and increased fetal nucleated red blood cells, consistent with prolonged impaired oxygen delivery. <b>Conclusion</b> This case highlights the unpredictable and acute nature of fetal compromise in pregnancies complicated by SCD, which may occur prior to guideline-recommended antenatal surveillance. Although prophylactic transfusion remains controversial, emerging evidence suggests a potential benefit in selecting high-risk patients. Early multidisciplinary management, individualized transfusion strategies, and heightened vigilance for sudden fetal decompensation are essential to improving perinatal outcomes in SCD.</p>","PeriodicalId":7645,"journal":{"name":"AJP Reports","volume":"16 2","pages":"e96-e100"},"PeriodicalIF":0.6,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13129312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147809382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discrepant Results on Two Different Single Gene Non-invasive Prenatal Tests for Cystic Fibrosis: A Case Report.","authors":"James P Hogg","doi":"10.1055/a-2844-4548","DOIUrl":"https://doi.org/10.1055/a-2844-4548","url":null,"abstract":"<p><p><b>Background</b> Prenatal cell-free DNA (cfDNA) screening has revolutionized the prenatal detection of fetal aneuploidy and other conditions. Originally designed to identify risk for trisomy 21, cfDNA screening has expanded to other fetal aneuploidies, microdeletion syndromes, dominant de novo single-gene disorders, and now autosomal-recessive single-gene conditions. The advancement of cfDNA screening offers patients and providers more options for prenatal risk assessment. <b>Case</b> A 34-year-old G2P1001 patient received a false-negative result from one single-gene noninvasive prenatal testing (sgNIPT), also known as prenatal single-gene cfDNA screening, for fetal cystic fibrosis, followed by a discrepant true-positive result on a different sgNIPT platform. The patient has a prior child affected with cystic fibrosis. The second laboratory returned a high-risk result for fetal cystic fibrosis, which was confirmed with diagnostic amniocentesis. <b>Conclusion</b> Prenatal sgNIPT screening should be individualized after appropriate counseling on the benefits and limitations of available screening and diagnostic tests. While diagnostic amniocentesis remains the society-recommended gold standard for prenatal diagnosis of autosomal-recessive conditions, these new, noninvasive technologies provide more options for patients who either do not want to assume the risks associated with or to better guide decision-making for diagnostic testing.</p>","PeriodicalId":7645,"journal":{"name":"AJP Reports","volume":"16 2","pages":"e90-e92"},"PeriodicalIF":0.6,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13095397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147759827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late-Onset Hypoparathyroidism-Induced Hypocalcemia in a Very Low Birth Weight Infant Caused by Undiagnosed Maternal Hyperparathyroidism.","authors":"Arne Beyer, Meike Franssen, Kai Böckenholt, Jonas Rohde, Ester Domning, Florian Schneider","doi":"10.1055/a-2837-6826","DOIUrl":"https://doi.org/10.1055/a-2837-6826","url":null,"abstract":"<p><strong>Objective: </strong>To describe a rare case of late-onset neonatal hypocalcemia in a very preterm infant caused by maternal adenoma-related hyperparathyroidism (HyperPT) and to discuss diagnostic and therapeutic implications.</p><p><strong>Study design: </strong>Case report of a preterm infant born at 29 weeks of gestation with very low birth weight. Clinical course, laboratory findings, maternal history, and management were reviewed to identify the etiology and guide treatment.</p><p><strong>Results: </strong>The infant developed transient, asymptomatic hypocalcemia during the neonatal period. Maternal evaluation revealed primary HyperPT due to a parathyroid adenoma as the underlying cause. The newborn responded to calcium supplementation and optimized vitamin D therapy.</p><p><strong>Conclusion: </strong>Maternal HyperPT can cause delayed neonatal hypocalcemia even in preterm infants. Early recognition through coordinated maternal-neonatal evaluation is crucial. Optimal vitamin D administration and close interdisciplinary communication between obstetrics and neonatology are essential for prevention and management.</p>","PeriodicalId":7645,"journal":{"name":"AJP Reports","volume":"16 2","pages":"e83-e89"},"PeriodicalIF":0.6,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13078914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147687677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chorionic Villi Sampling among Early and Late Gestational Age: Does Timing Affect Yield and Outcomes?","authors":"Julia Kim, Amberly Lao, Annie Rozenblyum, Lamia Alamri, Abigail Ludwigson, Teresa Dunn, Andrei Rebarber, Jennifer Lam-Rachlin, Manesha Putra, Martin Chavez, Patricia Rekawek, Lakha Prasannan","doi":"10.1055/a-2837-7068","DOIUrl":"https://doi.org/10.1055/a-2837-7068","url":null,"abstract":"<p><strong>Background: </strong>Chorionic villus sampling (CVS) is a diagnostic procedure that can be performed between 10 ^0/7 and 13 ^6/7 weeks to detect genetic abnormalities; however, a majority of providers opt to perform CVS after 11 weeks. This study evaluated the feasibility of CVS performed at varying gestational ages, comparing chorionic villi (CV) yield and procedural outcomes among early, typical, and late procedures.</p><p><strong>Materials and methods: </strong>This multicenter retrospective study included patients with CVS categorized as early (10 ^0/7 -10 ^6/7 weeks), typical (11 ^0/7 -13 ^6/7 weeks), and late CVS (≥14 ^0/7 weeks). The primary outcome was median CV weight. Secondary outcomes included need for culture, time to microarray results, and a subanalysis of abnormal chromosomal microarray analysis (CMA) results, obstetric, and neonatal outcomes.</p><p><strong>Results: </strong>Of 719 patients, 8.1% underwent early, 83.2% typical, and 8.8% late CVS. The early cohort had a lower body mass index (BMI). Early CVS was most frequently performed transvaginally and for the indication of prior affected pregnancy, and less likely for abnormal genetic screening or ultrasound findings. Median villi weight did not differ significantly, and 89% of all procedures yielded adequate tissue, defined as ≥5 mg. The time to the microarray result was shortest in the typical group. There were no significant differences in other secondary outcomes of need for culture, number of passes, or procedure-related complication rates. There was no case of limb anomalies.</p><p><strong>Conclusion: </strong>CVS performed before 11 weeks and after 14 weeks demonstrated comparable microarray outcomes and demonstrate the technical feasibility and diagnostic adequacy of CVS performed outside the typical gestational window. The results also support the availability of early CVS for cytogenetic testing in early pregnancy loss, where management may not allow for direct tissue testing. Prospective studies are warranted to validate these results and refine recommendations for optimal timing of CVS.</p>","PeriodicalId":7645,"journal":{"name":"AJP Reports","volume":"16 2","pages":"e77-e82"},"PeriodicalIF":0.6,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13056434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147637971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Application of the After-Action Review Technique for Therapeutic Debriefing after Unscheduled Cesarean Births.","authors":"Elena Lands, Sanjana Ghosh, Anna Binstock, Allison Serra","doi":"10.1055/a-2837-6754","DOIUrl":"10.1055/a-2837-6754","url":null,"abstract":"<p><strong>Objective: </strong>While birth-related posttraumatic stress disorder (PTSD) rates are rising, obstetric providers are ill-equipped to lead the trauma response. To address this need, we employed the After-Action Review (AAR) method in semistructured interviews with patients who recently underwent unanticipated cesarean deliveries. We performed qualitative analyses to determine if the AAR technique could (1) provide a therapeutic outlet to patients who experienced trauma and (2) elicit patient-derived quality improvement opportunities.</p><p><strong>Study design: </strong>Twenty patients and their support people were interviewed during the delivery admission, 3 months postpartum, and via an anonymous survey. Two independent coders analyzed transcripts and themes were generated inductively.</p><p><strong>Results: </strong>All surveyed patients found this process helpful, and 80% suggested an improvement, including educating patients about cesareans earlier and designating a specific staff member to support the patient during a cesarean or code. Five main themes emerged: (1) Mental adaptation to new care plan (reported by 95%), (2) prioritizing safety of baby (85%), (3) external influences on birth expectations (70%), (4) importance of support from various team members (85%), and (5) balance between autonomy and desiring definitive recommendations (75% vs. 30%). Interviewers found the technique easy to apply.</p><p><strong>Conclusion: </strong>AAR provides a novel, effective, and reproducible mechanism for therapeutic debriefing and generating patient-centered opportunities to improve care within obstetrics.</p>","PeriodicalId":7645,"journal":{"name":"AJP Reports","volume":"16 1","pages":"e67-e71"},"PeriodicalIF":0.6,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13035413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147589305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Pilot Study Evaluating Associations between Continuous Glucose Monitoring Metrics in Pregnancy and Postpartum A1c and Blood Pressure.","authors":"Chloe F Michalopoulos, Diana C Soria-Contreras, Sarah Hsu, Robin Azevedo, Arantxa Medina Baez, Emily A Rosenberg, Camille E Powe","doi":"10.1055/a-2837-6898","DOIUrl":"10.1055/a-2837-6898","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to examine the relationship between continuous glucose monitoring (CGM) metrics during gestational diabetes mellitus (GDM)-affected pregnancy and postpartum cardiometabolic measures in a pilot study.</p><p><strong>Study design: </strong>We enrolled participants >6 months postpartum from a previous GDM trial where they wore a CGM during the third trimester. At the postpartum visit, we assessed hemoglobin A1c (HbA1c) and blood pressure (BP). We used linear regression models adjusted for age and body mass index (BMI) at the time of CGM wear to test for a relationship between pregnancy CGM metrics (mean glucose, coefficient of variation, time in pregnancy range 63-140 mg/dL [pTIR], time >120 and >140 mg/dL) and postpartum outcomes (HbA1c and BP).</p><p><strong>Results: </strong>Of 14 eligible participants with pregnancy CGM data, 11 (79%) returned at a mean of 20.3 months postpartum (range 11-33). Age and BMI during pregnancy CGM wear were 36.0 (2.7) years and 28.7 (5.5) kg/m ² ; gestational age was 32.0 (2.0) weeks. Higher pTIR was associated with lower postpartum HbA1c ( <i>n</i>  = 8, β = -0.06, <i>p</i>  = 0.007). Other CGM metrics were not associated with HbA1c. There were no associations between CGM metrics and BP.</p><p><strong>Conclusion: </strong>Third-trimester CGM pTIR should be tested as a predictor of postpartum glycemia in a larger study.</p>","PeriodicalId":7645,"journal":{"name":"AJP Reports","volume":"16 1","pages":"e72-e76"},"PeriodicalIF":0.6,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13035414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147589328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Freeze-Dried Mother's Own Milk for Novel Fortification in a Late Preterm Infant with Complicated Intestinal Atresia and Congenital Shortened Bowel: A Case Report.","authors":"Allyson Ward, Sarah M Reyes, Berkley Luck, Laura Serke, Lauren Figard, Amy Kimball","doi":"10.1055/a-2832-1849","DOIUrl":"10.1055/a-2832-1849","url":null,"abstract":"<p><strong>Objective: </strong>Feeding intolerance and growth failure commonly complicate recovery in infants with complicated intestinal atresia, often requiring prolonged human milk fortification after hospital discharge. Our objective was to describe a novel fortification strategy that enabled an exclusive mother's own milk (MOM) diet during postdischarge fortification in a medically complex infant with feeding intolerance.</p><p><strong>Study design: </strong>This case report details the use of freeze-dried mother's own milk (FDMOM) to fortify expressed MOM in a late preterm infant with complicated atresia and congenital shortened bowel to resolve feeding intolerance and weight faltering. Freeze-drying of MOM took place at a commercial facility using SafeDry, a patented contact-free process. FDMOM was used to increase the caloric density of expressed MOM under medical supervision using a targeted fortification approach.</p><p><strong>Results: </strong>The patient tolerated unfortified MOM but developed severe fussiness, abdominal distention, and increased stooling upon fortification with hypoallergenic formulas. These symptoms resolved within 24 hours of transitioning to FDMOM fortification. Remarkably, the infant went from the 24th percentile for weight-for-age to the 66th percentile within 86 days.</p><p><strong>Conclusion: </strong>FDMOM fortification may represent a novel, well-tolerated strategy to support growth while maintaining an exclusive MOM diet in infants after complex gastrointestinal surgery and hospital discharge.</p>","PeriodicalId":7645,"journal":{"name":"AJP Reports","volume":"16 1","pages":"e63-e66"},"PeriodicalIF":0.6,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transient Neonatal Cyanosis Exacerbated by Inhaled Nitric Oxide.","authors":"Kaquanta Barlow, Charles J Sadle, Vidhi Jhaveri, Nicole Cacho, Timothy E Albertson, Payam Vali, Joseph J Shen, Satyan Lakshminrusimha","doi":"10.1055/a-2821-3305","DOIUrl":"10.1055/a-2821-3305","url":null,"abstract":"<p><strong>Background: </strong>Methemoglobinemia in newborns presents with cyanosis and hypoxemia, which can be mistaken for congenital heart disease or pulmonary hypertension.</p><p><strong>Case report: </strong>A term infant presented with cyanosis and low SpO ₂ (70s) immediately after birth, despite continuous positive airway pressure (CPAP) and 100% inspired oxygen. The patient was intubated and started on inhaled nitric oxide (iNO) and prostaglandin E1 infusion. Chest X-ray showed bilateral pneumothoraces; the echocardiogram was normal. Arterial blood gases demonstrated normal pH and elevated PaO ₂ . iNO and prostaglandin E1 (PGE1) were discontinued. Attempts to obtain methemoglobin levels via a co-oximeter panel were unsuccessful, presumably due to out-of-range values. The infant's father revealed that he also had transient cyanosis as an infant. The infant was treated with ascorbic acid. A blood sample sent to a reference laboratory a day after discontinuation of inhaled NO showed a methemoglobin level of 10.2%. Targeted gamma globin gene sequencing found a heterozygous likely pathogenic variant in hemoglobin subunit gamma 2 (HBG2) (p.His63Tyr). He was discharged home at 1 week of age on room air.</p><p><strong>Conclusion: </strong>Hereditary causes of methemoglobinemia should be considered for newborns with persistent cyanosis with low SpO ₂ and elevated PaO ₂ . Detailed family history and avoiding triggers of methemoglobinemia, such as iNO, are the cornerstones of management.</p>","PeriodicalId":7645,"journal":{"name":"AJP Reports","volume":"16 1","pages":"e59-e62"},"PeriodicalIF":0.6,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12995450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid Normalization of Amniotic Fluid Index Following Discontinuation of Olmesartan: A Case Report.","authors":"Annika Van Oosbree, Therese Larson, Hannah Conley, Matthew Bridges, Pedro Argoti, Giancarlo Mari","doi":"10.1055/a-2816-0125","DOIUrl":"https://doi.org/10.1055/a-2816-0125","url":null,"abstract":"<p><strong>Background: </strong>Angiotensin II receptor blockers (ARBs) are commonly used for hypertension but are contraindicated in pregnancy due to risks of oligohydramnios, renal dysgenesis, and pulmonary hypoplasia from suppression of the fetal renin-angiotensin system. Olmesartan, a frequently prescribed ARB, has a longer receptor binding half-life and higher affinity than other ARBs, producing more potent and sustained antihypertensive effects. Emerging evidence suggests that stopping ARBs during pregnancy may allow recovery of amniotic fluid and renal function.</p><p><strong>Case: </strong>A 30-year-old primigravida with chronic hypertension presented at 24 weeks' gestation while taking olmesartan. Ultrasound revealed anhydramnios with a normal-appearing fetal genitourinary tract. Olmesartan was discontinued and replaced with labetalol. Within 2 weeks, the amniotic fluid index normalized, and subsequent ultrasounds showed sustained recovery. At 34 weeks, she delivered a viable male infant with reassuring renal function and only mild, improving calyceal dilation on postnatal ultrasound.</p><p><strong>Conclusion: </strong>This is, to our knowledge, the first reported case of reversible anhydramnios associated with first- and second-trimester olmesartan exposure. The favorable outcome highlights the potential for reversibility of ARB-related fetopathy with timely cessation. Clinicians should consider serial ultrasound monitoring before recommending termination, as early drug withdrawal may restore amniotic fluid and support normal neonatal outcomes.</p>","PeriodicalId":7645,"journal":{"name":"AJP Reports","volume":"16 1","pages":"e54-e58"},"PeriodicalIF":0.6,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12971268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating the Twist: An Atypical Presentation of Malrotation.","authors":"Shivangi Ganeshan, Kimberley R Zakka, Arash R Zandieh, Manuel B Torres, Lewis P Rubin","doi":"10.1055/a-2803-3478","DOIUrl":"10.1055/a-2803-3478","url":null,"abstract":"<p><p>Intestinal malrotation is a congenital anomaly resulting from abnormal midgut rotation and fixation and occurs in approximately 1 in 500 live births. Malrotation results in a narrow mesenteric root, predisposing to midgut volvulus and potentially life-threatening bowel ischemia. Symptoms develop in about 1 in 6,000 individuals, over 75% of cases presenting in the early neonatal period. Bilious vomiting and abdominal distension are common signs of presentation. We report a case of a healthy term male neonate who was breastfeeding with formula supplementation until day of life 3, when he passed two bloody stools. He was transferred to our neonatal intensive care unit for evaluation and management. Abdominal ultrasound demonstrated pathognomonic reversal of the relationship between the superior mesenteric artery and superior mesenteric vein and an upper gastrointestinal (GI) contrast study confirmed intestinal malrotation. He underwent an urgent exploratory laparotomy and corrective Ladd procedure. There was no intraoperative evidence of volvulus or bowel ischemia. He had an uncomplicated recovery and was discharged several days later. GI bleeding is a rare initial presentation of malrotation, particularly in the absence of bilious emesis. This case emphasizes the importance of considering malrotation in neonates with hematochezia to enable early diagnosis and prevent life-threatening complications.</p>","PeriodicalId":7645,"journal":{"name":"AJP Reports","volume":"16 1","pages":"e50-e53"},"PeriodicalIF":0.6,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12962794/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147375866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}